CIVITAS THERAPEUTICS
Civitas Therapeutics is a biopharmaceutical company that focuses on developing pulmonary delivery therapies. The Company develops therapeutics for the treatment of central nervous system and respiratory disorders. It serves patients throughout the United States.
CIVITAS THERAPEUTICS
Industry:
Biopharma Biotechnology Life Science Therapeutics
Founded:
2009-01-01
Address:
Chelsea, Massachusetts, United States
Country:
United States
Website Url:
http://www.civitastherapeutics.com
Total Employee:
251+
Status:
Active
Contact:
617-660-4110
Email Addresses:
[email protected]
Total Funding:
122 M USD
Technology used in webpage:
Amazon GoDaddy DNS Amazon Virginia Region Symantec.cloud
Similar Organizations
AffyImmune Therapeutics
AffyImmune Therapeutics is a biopharmaceutical company developing genetically engineered immune cells to fight cancer.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Alloy Therapeutics
Alloy Therapeutics is a biotech company that makes medicine by democratizing access to foundational drug discovery platforms and services.
Animal Bioscience
Animal Bioscience is a pet platform.
Aptevo Therapeutics
Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market.
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Eikonoklastes Therapeutics
Eikonoklastes Therapeutics is a preclinical-stage biopharmaceutical company developing next-generation tissue factor (TF) immunotherapies.
Intensity Therapeutics
Intensity Therapeutics is a biopharmaceutical company that provides chemotherapy treatment for cancer patients.
Monopar
Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.
Quorum Innovations
Quorum Innovations is a biopharmaceutical company that focuses on developing human microbiome therapeutics.
Stelis Biopharma
Stelis Biopharma is a biopharmaceutical company that delivers affordable treatments to patients in both emerging and developed markets.
Current Advisors List
Current Employees Featured
Founder
Investors List
OrbiMed
OrbiMed investment in Series C - Civitas Therapeutics
Bay City Capital
Bay City Capital investment in Series C - Civitas Therapeutics
Longitude Capital
Longitude Capital investment in Series C - Civitas Therapeutics
Alkermes
Alkermes investment in Series C - Civitas Therapeutics
Sofinnova Investments
Sofinnova Investments investment in Series C - Civitas Therapeutics
Rock Springs Capital
Rock Springs Capital investment in Series C - Civitas Therapeutics
RA Capital Management
RA Capital Management investment in Series C - Civitas Therapeutics
Wellington Management
Wellington Management investment in Series C - Civitas Therapeutics
Partner Fund Management
Partner Fund Management investment in Series C - Civitas Therapeutics
Canaan Partners
Canaan Partners investment in Series C - Civitas Therapeutics
Official Site Inspections
http://www.civitastherapeutics.com
- Host name: ec2-3-82-161-243.compute-1.amazonaws.com
- IP address: 3.82.161.243
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Civitas Therapeutics"
Civitas Therapeutics - Crunchbase Company Profile
Organization. Civitas Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. …See details»
Civitas Therapeutics Company Profile 2024: Valuation, …
Civitas Therapeutics General Information Description. Civitas Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing …See details»
Civitas Therapeutics Company Profile | Management and
Civitas Therapeutics Profile and History Civitas is a biopharmaceutical company focused on developing and commercializing transformative therapeutics using its proprietary ARCUSTM …See details»
Civitas Therapeutics, Inc. Company Profile | Pearl River, NY ...
Find company research, competitor information, contact details & financial data for Civitas Therapeutics, Inc. of Pearl River, NY. Get the latest business insights from Dun & Bradstreet.See details»
Civitas Therapeutics - Company Profile - BizStanding
Company Profile. Industry: Biotechnology Site: civitastherapeutics.com Description: Civitas Therapeutics is a privately-held biopharmaceutical company focused on developing a robust …See details»
Civitas Therapeutics Inc - Company Profile and News
Company profile page for Civitas Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
Civitas Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Civitas Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, 5 news.See details»
Civitas Therapeutics Information - RocketReach
Civitas Therapeutics is a privately-held biopharmaceutical company focused on developing a robust pipeline of inhaled therapeutics with the clinically-proven ARCUS dry powder …See details»
Civitas Therapeutics Company Overview, Contact Details
Learn more about Civitas Therapeutics's company details, contact information, competitors, and more. Find accurate contact data easily with LeadIQ. Book a demo today.See details»
Civitas Therapeutics - VentureRadar
Civitas Therapeutics Secures $55 Million in Series C Financing. Source: businesswire.com. Venture-funding News. Equity Funding. 11 Sep 2013. Civitas Therapeutics Completes $38M …See details»
Civitas Therapeutics - Company Profile - Tracxn
6 days ago Civitas Therapeutics is a biopharmaceutical company focused on developing a robust pipeline of inhaled therapeutics with the clinically-proven ARCUS dry powder …See details»
Acorda Therapeutics Completes Acquisition of Civitas Therapeutics
Oct 22, 2014 Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced it has completed its acquisition of Civitas Therapeutics and obtained global rights to CVT-301, a Phase 3 treatment …See details»
Acorda Therapeutics to Acquire Civitas Therapeutics
Sep 24, 2014 Obtains global rights for Phase 3 Parkinson’s disease treatment Acquisition leverages existing Acorda development and commercial capabilities Company to host webcast …See details»
Civitas Therapeutics - Contacts, Employees, Board Members, …
Organization. Civitas Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. Number of …See details»
CIVITAS THERAPEUTICS Revenue, Growth & Competitor Profile
Determine whether Civitas Therapeutics grew or shrank during the last recession. This is useful in estimating the financial strength and credit risk of the company. Compare how recession-proof …See details»
Civitas Ditches IPO, Will Be Acquired - PitchBook
Sep 26, 2014 Acorda Therapeutics (NASDAQ: ACOR) has entered into an agreement to acquire Civitas Therapeutics, a biopharma developing respiratory drug delivery technologies, for $525 …See details»
Acorda Therapeutics : to Acquire Civitas Therapeutics
Sep 24, 2014 Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it entered into an agreement to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, …See details»
Civitas Therapeutics Secures $38 Million in Financing
Sep 11, 2013 Civitas' lead program, CVT-301, is an inhaled formulation of L-dopa being developed for the rapid and reliable relief from debilitating motor fluctuations (OFF episodes) …See details»
Civitas Therapeutics Brings Fundraising Total to $118M
Civitas Therapeutics has raised a $55 million Series C round from a host of investors including Canaan Partners, Sofinnova Ventures, Bay City Capital and OrbiMed Advisors, among …See details»
Civitas Therapeutics | Insights
Oct 17, 2018 Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»